MA46643A - Méthodes et compositions pour le mappage d'arn - Google Patents
Méthodes et compositions pour le mappage d'arnInfo
- Publication number
- MA46643A MA46643A MA046643A MA46643A MA46643A MA 46643 A MA46643 A MA 46643A MA 046643 A MA046643 A MA 046643A MA 46643 A MA46643 A MA 46643A MA 46643 A MA46643 A MA 46643A
- Authority
- MA
- Morocco
- Prior art keywords
- compositions
- methods
- rna mapping
- rna
- mapping
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662412932P | 2016-10-26 | 2016-10-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA46643A true MA46643A (fr) | 2019-09-04 |
Family
ID=62025494
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA046643A MA46643A (fr) | 2016-10-26 | 2017-10-26 | Méthodes et compositions pour le mappage d'arn |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US20180274009A1 (fr) |
| EP (1) | EP3532613A4 (fr) |
| MA (1) | MA46643A (fr) |
| WO (1) | WO2018081462A1 (fr) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| HRP20220070T1 (hr) | 2014-04-23 | 2022-04-01 | Modernatx, Inc. | Cjepiva nukleinske kiseline |
| US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
| EP3324979B1 (fr) | 2015-07-21 | 2022-10-12 | ModernaTX, Inc. | Vaccins contre une maladie infectieuse |
| WO2017031232A1 (fr) | 2015-08-17 | 2017-02-23 | Modernatx, Inc. | Procédés de préparation de particules et compositions associées |
| JP2018531290A (ja) | 2015-10-22 | 2018-10-25 | モデルナティーエックス， インコーポレイテッド | 性感染症ワクチン |
| DK3718565T3 (da) | 2015-10-22 | 2022-06-20 | Modernatx Inc | Vacciner mod respiratorisk virus |
| JP6921833B2 (ja) | 2015-10-22 | 2021-08-18 | モデルナティーエックス， インコーポレイテッド | ヒトサイトメガロウイルスワクチン |
| WO2017070624A1 (fr) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Vaccins contre des maladies tropicales |
| JP6925688B2 (ja) | 2015-10-22 | 2021-08-25 | モデルナティーエックス， インコーポレイテッド | 水痘帯状疱疹ウイルス（ｖｚｖ）のための核酸ワクチン |
| SI3386484T1 (sl) | 2015-12-10 | 2022-06-30 | Modernatx, Inc. | Sestave in metode za dovajanje terapevtskih sredstev |
| KR20230074598A (ko) | 2016-05-18 | 2023-05-30 | 모더나티엑스, 인크. | 릴랙신을 인코딩하는 폴리뉴클레오타이드 |
| SG11201901941YA (en) | 2016-09-14 | 2019-04-29 | Modernatx Inc | High purity rna compositions and methods for preparation thereof |
| JP6980780B2 (ja) | 2016-10-21 | 2021-12-15 | モデルナティーエックス， インコーポレイテッド | ヒトサイトメガロウイルスワクチン |
| US10925958B2 (en) | 2016-11-11 | 2021-02-23 | Modernatx, Inc. | Influenza vaccine |
| US11103578B2 (en) | 2016-12-08 | 2021-08-31 | Modernatx, Inc. | Respiratory virus nucleic acid vaccines |
| US11384352B2 (en) | 2016-12-13 | 2022-07-12 | Modernatx, Inc. | RNA affinity purification |
| EP3582790A4 (fr) | 2017-02-16 | 2020-11-25 | ModernaTX, Inc. | Compositions immunogènes très puissantes |
| EP3609534A4 (fr) | 2017-03-15 | 2021-01-13 | ModernaTX, Inc. | Vaccin à large spectre contre le virus de la grippe |
| WO2018170256A1 (fr) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Vaccin contre le virus de l'herpès simplex |
| WO2018170270A1 (fr) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Vaccin contre le virus varicelle-zona |
| WO2018170260A1 (fr) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Vaccin contre le virus respiratoire syncytial |
| WO2018170347A1 (fr) | 2017-03-17 | 2018-09-20 | Modernatx, Inc. | Vaccins à base d'arn contre des maladies zoonotiques |
| US11905525B2 (en) | 2017-04-05 | 2024-02-20 | Modernatx, Inc. | Reduction of elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins |
| EP3638215A4 (fr) | 2017-06-15 | 2021-03-24 | Modernatx, Inc. | Formulations d'arn |
| WO2019036683A1 (fr) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | Procédés analytiques par hplc |
| MA49913A (fr) | 2017-08-18 | 2021-05-05 | Modernatx Inc | Variants d'arn polymérase |
| WO2019036685A1 (fr) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | Procédés pour analyse par clhp |
| AU2018326799A1 (en) | 2017-08-31 | 2020-02-27 | Modernatx, Inc. | Methods of making lipid nanoparticles |
| EP3681514A4 (fr) | 2017-09-14 | 2021-07-14 | ModernaTX, Inc. | Vaccins à arn contre le virus zika |
| EP3724355A1 (fr) * | 2017-12-15 | 2020-10-21 | Novartis AG | Analyse de longueur de queue poly(a) d'arn par spectrométrie de masse |
| MA54676A (fr) | 2018-01-29 | 2021-11-17 | Modernatx Inc | Vaccins à base d'arn contre le vrs |
| US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
| CA3130888A1 (fr) | 2019-02-20 | 2020-08-27 | Modernatx, Inc. | Variants d'arn polymerase pour le coiffage co-transcriptionnel |
| US11851694B1 (en) | 2019-02-20 | 2023-12-26 | Modernatx, Inc. | High fidelity in vitro transcription |
| MX2022001664A (es) | 2019-08-09 | 2022-07-19 | Nutcracker Therapeutics Inc | Aparato microfluídico y metodos de uso del mismo. |
| AU2020348860A1 (en) * | 2019-09-19 | 2022-04-07 | Modernatx, Inc. | Cap guides and methods of use thereof for RNA mapping |
| JP2021185136A (ja) | 2020-04-22 | 2021-12-09 | ビオエンテッヒ・アールエヌエイ・ファーマシューティカルズ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | コロナウイルスワクチン |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
| AU2022249357A1 (en) * | 2021-04-01 | 2023-10-12 | Modernatx, Inc. | Methods for identification and ratio determination of rna species in multivalent rna compositions |
| US20230111049A1 (en) * | 2021-10-08 | 2023-04-13 | Waters Technologies Corporation | Sample preparation for lc-ms based sequence mapping of nucleic acids |
| WO2024002985A1 (fr) | 2022-06-26 | 2024-01-04 | BioNTech SE | Vaccin contre le coronavirus |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8911948B2 (en) * | 2008-04-30 | 2014-12-16 | Integrated Dna Technologies, Inc. | RNase H-based assays utilizing modified RNA monomers |
| US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
| US20160032273A1 (en) * | 2013-03-15 | 2016-02-04 | Moderna Therapeutics, Inc. | Characterization of mrna molecules |
| WO2017031241A1 (fr) * | 2015-08-17 | 2017-02-23 | Modernatx, Inc. | Cartographie/profilage de l'arn |
-
2017
- 2017-10-26 WO PCT/US2017/058591 patent/WO2018081462A1/fr unknown
- 2017-10-26 MA MA046643A patent/MA46643A/fr unknown
- 2017-10-26 EP EP17865334.1A patent/EP3532613A4/fr active Pending
-
2018
- 2018-06-06 US US16/001,765 patent/US20180274009A1/en not_active Abandoned
-
2022
- 2022-06-29 US US17/852,974 patent/US20230212645A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018081462A1 (fr) | 2018-05-03 |
| US20180274009A1 (en) | 2018-09-27 |
| EP3532613A4 (fr) | 2020-05-06 |
| US20230212645A1 (en) | 2023-07-06 |
| EP3532613A1 (fr) | 2019-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA46643A (fr) | Méthodes et compositions pour le mappage d'arn | |
| MA49421A (fr) | Formulations d'arn | |
| MA49913A (fr) | Variants d'arn polymérase | |
| MA46481A (fr) | Compositions d'oligonucléotides et méthodes associées | |
| MA49403A (fr) | Compositions de pde5 et méthodes d'immunothérapie | |
| MA44479A (fr) | Arn transrepliquant | |
| MA45188A (fr) | Oligonucléotides, compositions et méthodes associées | |
| MA50269A (fr) | Compositions d'acides nucléiques-polypeptides et méthodes d'induction de saut d'exon | |
| DK3804737T3 (da) | Sammensætninger omfattende bakteriestammer | |
| MA47680A (fr) | Arn thérapeutique | |
| MA50833A (fr) | Compositions et méthodes pour l'édition génique pour l'hémophilie a | |
| MA55629A (fr) | Compositions d'anticorps pour le traitement de tumeurs | |
| FR3016945B1 (fr) | Plaque d'amortissement | |
| EP3464313A4 (fr) | Nucléotides modifiés 5 '-cyclo-phosphonate | |
| MA46963A (fr) | Méthodes pour déterminer le dosage de céllules car-t | |
| MA45656A (fr) | Nouveaux pyrimidine carboxamides utilisées comme inhibiteurs de l'enzyme vanin-1 | |
| MA43378A (fr) | Compositions et méthodes pour la reduction de la réponse immunitaire contre récepteurs d'antigène chimériques | |
| DK3600363T3 (da) | Sammensætninger omfattende bakteriestammer | |
| FR3016407B1 (fr) | Boitier d'entrainement pour equipements | |
| FR3022462B1 (fr) | Composition orale d'anticorps anti-tnfalpha | |
| MA54143A (fr) | Compositions et méthodes | |
| MA49006A (fr) | Inhibiteurs d'ip6k | |
| MA49576A (fr) | Compositions et méthodes pour le traitement d'infections fongiques | |
| MA43230A (fr) | Méthodes et compositions pour le traitement d'une épidermolyse bulleuse | |
| MA53831A (fr) | Méthodes permettant de réduire l'agrégation d'anticorps bispécifiques |